ArticlePolymers2026
Development of 3D-Printable Lead-Free Composite Materials for Mixed Photon and Neutron Attenuation.
Article in Polymers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The growing use of radiation technologies has increased the need for shielding materials that are lightweight, safe, and adaptable to complex geometries. While lead remains highly effective, its toxicity and weight limit its suitability, driving interest in alternative materials. The process of 3D printing enables the rapid fabrication of customized shielding geometries; however, only limited research has focused on 3D-printed polymer composites formulated specifically for mixed photon-neutron fields. In this study, we developed a series of 3D-printable ABS-based composites incorporating tungsten (W), bismuth oxide (Bi
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.